Company Profile

Nanjing Delova Biotech Co., Ltd. (Delova Biotech) is a biotechnology company, focusing on the development of new drugs in the field of pain with unmet medical needs. The Company aims to provide patients with long-acting and highly effective non-opioid analgesic products and improve the quality of human health with scientific innovation.

 

The Company's vision is to become the world's leading new drug company in the field of pain.

 

The Company has created a rich product pipeline based on many independent intellectual property technology platforms such as extended and controlled release injection, topical transdermal technology, and solubility enhancement technology for insoluble drugs, with indications covering postoperative pain, aesthetic surgery pain, multiple neuropathic pains (DPN, PHN, etc.), osteoarthritis pain, migraine, trigeminal neuralgia, etc. Several products have entered the clinical development stage and are at the forefront of the new pain drugs in China.

 

The Company has established an R&D center in Nanjing, Jiangsu and a subsidiary in California, USA, with a total of nearly 50 full-time employees. We have built a new drug research and development team, composed of of formulation, quality research, preclinical research, clinical, and registration experts, and over 40% of our employees have more than 10 years of new drug R&D experience. Our team members have rich experience in business collaboration, project development, complex formulation research, clinical research, and registration of new drugs.

US · California Subsidiary Company
CN · Nanjing Headquarter (R&D Center )
R&D Concept

The Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development.

 

The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company’s product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements.

Founders
Investment Institutions
Qualifications and Honors